Previous Study: TRIO012
Next Study: TRIO014

Studies & Results


A Phase III study of ERBB2 positive advanced or metastatic gastric or esophageal or gastroesophageal junction adenocarcinoma treated with Capecitabine plus Oxaliplatin with or without Lapatinib

View FDA Study


ASCO Annual Meeting, 2015

Bang Y-J, Qin S, Chung H-C, et al

Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx).

ESMO/ECCO Congress, 2014

Chu MP, Hecht JR, Slamon D, et al

Proton Pump Inhibitor (ppis) Therapy May Impair Capecitabine (cape) Efficacy in Metastatic Gastroesophageal Cancer (gec), Results from the Trio-013/Logic Trial.

ASCO Annual Meeting, 2014

Press M, Grob T, Marx A, et al.

Concordance study of HER2 fluorescence in situ hybridization (FISH) assays in upper gastrointestinal (UGI) adenocarcinomas.

ASCO Annual Meeting, 2013

Hecht JR, Bang Y, Qin S, et al

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at